Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuanchen Liu

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Nature Communications|July 16, 2025
An orally available M<sup>pro</sup>/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivoHuiping Shuai, Jingxin Qiao, Chaemin Yoon, et al.
Nature Communications|December 11, 2025
Pathogenicity, virological features, and immune evasion of SARS-CoV-2 JN.1-derived variants including JN.1.7, KP.2, KP.3, and KP.3.1.1Jialu Shi, Xiaoyu Zhao, Xiaohui Jin, et al.
Nature Communications|October 8, 2024
Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3Yuanchen Liu, Xiaoyu Zhao, Jialu Shi, et al.
BMJ (Clinical Research Ed.)|January 14, 2021
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trialsSuetonia C Palmer, Britta Tendal, Reem A Mustafa, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Nature Communications|July 16, 2025
An orally available M<sup>pro</sup>/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivoHuiping Shuai, Jingxin Qiao, Chaemin Yoon, et al.
Nature Communications|December 11, 2025
Pathogenicity, virological features, and immune evasion of SARS-CoV-2 JN.1-derived variants including JN.1.7, KP.2, KP.3, and KP.3.1.1Jialu Shi, Xiaoyu Zhao, Xiaohui Jin, et al.
Nature Communications|October 8, 2024
Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3Yuanchen Liu, Xiaoyu Zhao, Jialu Shi, et al.
BMJ (Clinical Research Ed.)|January 14, 2021
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trialsSuetonia C Palmer, Britta Tendal, Reem A Mustafa, et al.
Pageof 4